Related Experiment Video
Updated: Aug 24, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies
Chung-Heng Liu1, Christopher L Bowlus2
1Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19129 USA.
Abstract:
Primary biliary cholangitis (PBC) is an autoimmune disease of the interlobular bile ducts leading to secondary damage of hepatocytes and may progress to cirrhosis and liver failure. The first-line treatment is ursodeoxycholic acid; up to 40% of patients do not have an adequate response and remain at risk of disease progression. Obeticholic acid has been conditionally approved for the treatment of PBC as add-on therapy and bezafibrate has shown similar efficacy in this group of patients. Several new therapies are in development and may further add to the treatment options available to patients with PBC.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Acute Pancreatitis II: Clinical Manifestations and Management
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

